Revenue” Never Actually Received
Today’s guest post, by Reed Smith’s Paul Melniczak and Erin Apsokardu, is a little different. It’s not about product liability, but rather about a state tax issue with the potential for saving drug companies substantial sums. Since a dollar is a dollar, whether it is saved from bogus product
What is it about law professors? They start out like the rest of us lawyers. They usually have the same backgrounds and receive the same legal educations we do. When the rest of us go into practice, we have to back up everything we say with facts, studies, testimony, cases, etc. But the statements of
We posted a few hours ago about the Amos tax case, and we gave our amateur opinion that it was unlikely to have much of an effect in the product liability area.
Professor James Maule, of Villanova, who blogs at Mauled Again, is less sanguine. He has suggested that, so long as confidentiality agreements
One of our colleagues recently called with a question about the tax treatment of settlement agreements that contain confidentiality provisions.
Apparently, the IRS is trying to capture some of the money that has been changing hands in settlements that are treated confidentially. Although the portion of the settlement payment made in compensation for personal injuries
As readers of this blog know, we root for the defense here.
We really have no choice. Since we represent drug and device companies in product liability cases for a living, we can’t publicly say things that could later be used against us (or our clients, or our colleagues). So we might occasionally have a